Story

US Prescription Growth Slows in Late July, Morgan Stanley Data Shows

ENTHMSVIIDZHZH-TWJAKOHI
Aug 7, 20262 min read
US Prescription Growth Slows in Late July, Morgan Stanley Data Shows
Text size
Background

Total U.S. prescription drug growth moderated in the final week of July, while several recently launched therapies from major pharmaceutical companies continued to show steady uptake. The latest weekly analysis from Morgan Stanley provides investors with a high-frequency look at demand trends across the pharmaceutical sector.

Overall Market Trends

For the week ending July 31, total prescription volume grew 1.5% year-over-year, a deceleration from the 2.0% growth recorded in the prior week, according to the report. This figure remains slightly above the rolling 12-week average growth rate of 1.3%.

However, more recent trends indicate some softness. The rolling 4-week year-over-year change was negative at -0.2%, and sequential growth from the previous week was also down -0.5%. These metrics suggest a potential near-term cooling in prescription demand.

Key Drug Launch Trajectories

The Morgan Stanley report detailed the prescription trends for several significant new drugs, which are closely monitored as indicators of future revenue streams.

Sample IUX Markets – In-articleAd
  • Bristol-Myers Squibb (BMY): *Cobenfy*, a treatment for schizophrenia, saw weekly prescriptions rise to approximately 3,370 from 3,290. The firm estimates the drug needs to reach about 186,000 total prescriptions to achieve 2026 consensus sales expectations of $271 million.
  • Gilead Sciences (GILD): *Yeztugo* prescriptions held steady at approximately 1,890. Morgan Stanley highlighted the drug's strong 95% payor coverage and a persistence rate above 70%, leading the firm to project U.S. sales of $1.05 billion, above the consensus estimate of $988 million.
  • Vertex Pharmaceuticals (VRTX): *Journavx*, for acute pain, recorded a script increase to approximately 26,970. The report noted that this IQVIA data does not capture hospital scripts, which Vertex says account for a 45% share of the drug's use.
  • Johnson & Johnson (JNJ): *Icotyde*, for plaque psoriasis, saw prescriptions tick up to 880. The company has now secured commercial payer coverage for over 50% of patients.

Biosimilar Competition Heats Up

The data also provides insight into the intensifying competition from biosimilars against established blockbuster drugs. In the market for biosimilars to Stelara, Biocon’s *Yesintek* holds a commanding 78% market share, while Amgen’s (AMGN) *Wezlana* has captured approximately 19%.

For biosimilars targeting Prolia, the branded drug retains a 53% share of total prescriptions. Among its challengers, Sandoz’s *Jubbonti* has secured a 26% share, while Celltrion’s *Stoboclo* stands at 14%. These figures are crucial for investors assessing the pace of sales erosion for originator products.

Read next

More on Stocks
Back to latest news

LATEST